ORAMED PHARMACEUTICALS Business Summary

Oramed Pharmaceuticals Inc. (ORMP) has evolved into a diversified biomedical innovation and investment firm, generating revenue through strategic asset realizations, licensing milestones, and a 4% royalty on net sales of Lifeward Ltd.’s ReWalk franchise. Following a landmark January 2026 transaction, the company transitioned its proprietary Protein Oral Delivery (POD™) platform to Lifeward in exchange for a 49.9% beneficial ownership stake, effectively merging its oral drug delivery R&D with a revenue-generating medical robotics business. Oramed’s primary segments now include strategic biopharmaceutical investments—highlighted by a $118 million return to date from its Scilex Holding Company position—and the continued clinical management of its oral insulin and GLP-1 analogs. In a competitive landscape featuring Rani Therapeutics, Entera Bio, and Novo Nordisk, Oramed distinguishes itself as a strategic holding entity that balances high-upside clinical assets with stable royalty streams and significant equity in commercial-stage partners. The company is led by co-founders Nadav Kidron (CEO and Chairman) and Dr. Miriam Kidron (Chief Scientific Officer), a prominent biochemist whose pioneering research at Jerusalem’s Hadassah-Hebrew University Medical Center serves as the scientific bedrock for the POD™ technology. Nadav Kidron, who holds an LL.B. and an International MBA, provides the strategic vision for the firm’s complex capital allocation and M&A activities, supported by CFO Avraham Gabay and COO Joshua Hexter. The leadership team is noted for its exceptional stability, with an average executive tenure exceeding 13 years, and is guided by a board that has historically included veterans from the diabetes and life sciences sectors. Oramed’s current profile is defined by its role as a major strategic investor in Lifeward and Scilex, reflecting a leadership philosophy that prioritizes shareholder value through diversified biomedical holdings and disciplined financial management.